• Japanese
  • Korean
  • Chinese
Cover Image

Diabetes, Metabolic Syndrome and Cardiovascular Disease

Abstract

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Methodology

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies. The editor of this report holds a Master's degree in immunology, and has substantial experience in science writing and as a medical industry analyst. She also has many years of laboratory experience investigating cancer immunotherapies, has conducted laboratory testing, and instrument and reagent development for biotech companies.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO), governmental entities like the U.S. Department of Health and Human Services (HHS), and U.S. Federal agencies such as National Institutes of Health (NIH), Food and Drug Administration (FDA) and the Centers of Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes.

Primary Sources

TriMark collects information from hundreds of Database Tables and mans comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TiMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industn association reports, government-alliliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. About This Report
  • 1.3. Scope of the Report
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Introduction

  • 2.1. Demographics of Diabetes
    • 2.1.1. Worldwide Diabetes
    • 2.1.2. U.S. Diabetes
  • 2.2. Economics of Diabetes

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes

  • 3.1. Pre-Diabetes Syndrome
  • 3.2. Metabolic Syndrome
  • 3.3. Diabetes and Inflammation
  • 3.4. Diagnosis of Diabetes Mellitus
  • 3.5. Progression of Diabetes
  • 3.6. Risk Factors and Diabetes
    • 3.6.1. Obesity
    • 3.6.2. Stress-Induced Hyperglycemia
  • 3.7. Complications and Co-Morbidities in Type 2 Diabetes
    • 3.7.1. Preventing Complications and Co-Morbidities in Diabetes
  • 3.8. Hypoglycemia Resulting From Treatment
  • 3.9. Cardiovascular Disease (CVD)
    • 3.9.1. CVD Facts
    • 3.9.2. Cardiac Care Therapeutics
  • 3.9.2.1. Anti-Hypertensive Drugs
    • 3.9.2.2. Cholesterol Management Drugs
    • 3.9.2.3. Anticoagulants
  • 3.9.3. CVD Diagnostics

4. Pharmaceutical Industry and the Anti-Diabetes Market

  • 4.1. The Worldwide Pharmaceutical Industry
    • 4.1.1. Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
    • 4.1.2. Global Pharmaceutical Market
  • 4.2. Total Diabetes Drug Market Size and Growth
    • 4.2.1. Sales of Anti-Diabetic Drugs Continue to Rise
  • 4.3. Diabetic Medications Overview
    • 4.3.1. Recent Trends in Diabetic Drug Usage
    • 4.3.2. Market Influence Factors

5. Non-Insulin Anti-Diabetes Products

  • 5.1. Anti-Diabetic Drug Therapy Overview
    • 5.1.1. Sulfonylureas
    • 5.1.2. Meglitinides
    • 5.1.3. Biguanides
    • 5.1.4. Thiazolidinediones (TZDs)
    • 5.1.5. α-Glucosidase Inhibitors
    • 5.1.6. Incretin Mimetics/Glucagon-Like Peptide (GLP-1) Analogs and Agonists
      • 5.1.6.1. Byetta (Exenatide)
      • 5.1.6.2. Victoza (Liraglutide)
      • 5.1.6.3. Bydureon (exenatide LAR)
    • 5.1.7. Amylin Analog
    • 5.1.8. DPP-IV Inhibitors
      • 5.1.8.1. Januvia (Sitagliptin)
      • 5.1.8.2. Onglyza (Saxagliptin)
      • 5.1.8.3. Tradjenta (Linagliptin)
    • 5.1.9. Combination Therapy
      • 5.1.9.1. Youth With Recent-Onset Type 2 Diabetes Should Be Started on Combination Therapies
    • 5.1.10. Comparisons of the Anti-Diabetes Drugs
  • 5.2. Drivers and Trends
    • 5.2.1. Market Share of Anti-Diabetic Drugs
    • 5.2.2. Forecasts for Anti-Diabetic Drugs
    • 5.2.3. Sales Forecast for the Global Diabetes Market
  • 5.3. The Future
    • 5.3.1. Practice Patterns
    • 5.3.2. New Products in Pipeline
      • 5.3.2.1. Novel GLP-1 Agonists and Analogs
      • 5.3.2.2. Novel DPP-IV Inhibitors
      • 5.3.2.3. Sodium Glucose Cotransporter 2 (SGLT-2)
      • 5.3.2.4. Emerging Non-Insulin Anti-Diabetes Targets and Drugs in the Pipeline
      • 5.3.2.5. Novel Approaches to Finding New Drug Targets
  • 5.4. Anti-Diabetic Drug Patent Expiry
  • 5.5. Regulatory Issues

6. Insulin

  • 6.1. Insulin Markets
    • 6.1.1. Major Players and Market Share
    • 6.1.2. Patent Expirations
    • 6.1.3. Innovation Strategies
  • 6.2. Insulin Therapeutics
    • 6.2.1. Recommendations for Insulin Initiation and Administration
    • 6.2.2. Short-Acting Insulin
    • 6.2.3. Rapid-Acting Insulin
    • 6.2.4. Intermediate-Acting Insulin
    • 6.2.5. Long-Acting Insulin
    • 6.2.6. Long-Acting Insulins in Development
    • 6.2.7. Insulin Mixtures
  • 6.3. Pipeline Insulin
  • 6.4. Non-Invasive Insulin Delivery
    • 6.4.1. Inhaled Insulin
      • 6.4.1.1. A Chronicle of Inhaled Insulins
    • 6.4.2. Oral Insulin
    • 6.4.3. Transdermal Insulin
  • 6.5. Barriers for Non-Injected Insulin
  • 6.6. Patient Potential for Non-Injected Insulin
  • 6.7. Insulin Delivery Devices
    • 6.7.1. Insulin Pens
    • 6.7.2. Injections Aids
      • 6.7.2.1. Automatic Injectors
      • 6.7.2.2. Syringe Magnifiers
      • 6.7.2.3. Injection Ports
    • 6.7.3. Insulin Jet Injectors
    • 6.7.4. Insulin Pumps
      • 6.7.4.1. External Insulin Pumps
      • 6.7.4.2. Insulin Patch Pumps in Development
      • 6.7.4.3. Implantable Insulin Pumps
      • 6.7.4.4. Insulin Pump Market Share
      • 6.7.4.5. Drivers of Demand for Pumps
  • 6.8. Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products

  • 7.1. Projections for the Anti-Diabetes Drug Market
  • 7.2. Artificial Pancreas
  • 7.3. Insulin-Producing Cells
    • 7.3.1. Cell Therapy Companies for Diabetes
  • 7.4. Transplantation Procedures
    • 7.4.1. Pancreatic Transplantation
      • 7.4.1.1. Pancreatic Organ Transplantation
      • 7.4.1.2. Allo-Islet Transplantation
      • 7.4.1.3. Transplantation of Encapsulated Pancreatic Cells
      • 7.4.1.4. Implantation of Genetically Engineered ?-Cells or Embryonic Stem Cells
    • 7.4.2. Current Status
  • 7.5. Gastric Bypass Surgery to Treat Type 2 Diabetes
  • 7.6. Immune Modulators
  • 7.7. Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
  • 7.8. Other Anti-Diabetic Therapy Drug Candidates
    • 7.8.1. Lipid Abnormalities
    • 7.8.2. High Blood Pressure
    • 7.8.3. Anticoagulants
  • 7.9. Drugs Used “Off-label”
    • 7.9.1. Warfarin Sodium

8. Diagnosing Diabetes Using In Vitro Laboratory Tests

  • 8.1. New Diagnostic Guidelines
  • 8.2. Diabetes Tests
    • 8.2.1. Fasting Plasma Glucose (FPG) Test
    • 8.2.2. Glucose Tolerance Test
    • 8.2.3. Test for Glycosylated Hemoglobin
    • 8.2.4. Fructosamine
  • 8.3. Glucose Monitoring
    • 8.3.1. Overview of Market Segment
    • 8.3.2. Competitive Strategies
    • 8.3.3. Analyses of the Current Market Conditions, Competition and Product Mix
      • 8.3.3.1. First-Generation Monitors
      • 8.3.3.2. Second-Generation Monitors
      • 8.3.3.3. Third-Generation SMBG Technologies
      • 8.3.3.4. Product Overview
    • 8.3.4. What Are the Advantages of Using a Continuous Glucose-Monitoring Device?
    • 8.3.5. Minimally-Invasive Continuous Glucose Monitors in Development
    • 8.3.6. Future of Non-Invasive Glucose Technology
    • 8.3.7. Lancets and Lancing Devices

9. Market Trends, Challenges and Strategic Options

  • 9.1. Overview
  • 9.2. Diabetes Drug Market Trends
    • 9.2.1. Overview
    • 9.2.2. Emergence of Therapeutics With Improved Administration Characteristics
    • 9.2.3. Increasing Prevalence of Obesity
  • 9.3. Diabetes Mellitus Market Challenges
    • 9.3.1. Overview
    • 9.3.2. Diabetic Pain Therapeutics
    • 9.3.3. Market Prospects of Inhalable Drugs and Their Ability to Establish Safety Levels
    • 9.3.4. Changing Consumer Preference Drives Product Development in Invasive Technology Segment
    • 9.3.5. Non-Invasive Technology for Revenue Potential
    • 9.3.6. Developing Countries Emerging as Key Markets for Diabetes Monitoring Devices
    • 9.3.7. Consumer-Driven Marketing Campaigns - Essential, Though Expensive
    • 9.3.8. Escalating Expenditure for R&D and Marketing Triggers Consolidation
  • 9.4. Strategic Options
    • 9.4.1. Overview
    • 9.4.2. Combined Self-Testing Glucose Monitor with Insulin Delivery
    • 9.4.3. Diabetes Drugs in Pipeline
  • 9.5. FDA Therapeutic Targets
    • 9.5.1. FDA Targets Cardiotoxicity
    • 9.5.2. Avandia FDA Warning
  • 9.6. Outlook to Anti-Diabetes Drugs
  • 9.7. Outlook for Cardiovascular Drugs
  • 9.8. Recent Industry Activity

10. Company Profiles

  • 10.1. A. Menarini
  • 10.2. Abbott Laboratories
  • 10.3. Amgen
  • 10.4. AstraZeneca
  • 10.5. Bayer
  • 10.6. BodyMedia
  • 10.7. Cybermedical
  • 10.8. Debiotech
  • 10.9. DexCom
  • 10.10. Echo Therapeutics
  • 10.11. Eli Lilly
  • 10.12. Elixir Pharmaceuticals
  • 10.13. Eksigent
  • 10.14. Flamel Technologies
  • 10.15. GlaxoSmithKline
  • 10.16. Insulet
  • 10.17. iSense Corporation
  • 10.18. Isis Pharmaceuticals, Inc.
  • 10.19. Johnson & Johnson
  • 10.20. KYORIN
  • 10.21. M-Biotech
  • 10.22. Medtronic
  • 10.23. Merck & Co.
  • 10.24. Merck KGaA
  • 10.25. MicroIslet
  • 10.26. Mitsubishi Tanabe Pharma Corporation
  • 10.27. Nipro Diabetes Systems
  • 10.28. Novartis
  • 10.29. Novo Nordisk
  • 10.30. Novocell
  • 10.31. ONO Pharmaceutical
  • 10.32. Orexigen Therapeutics
  • 10.33. Pfizer
  • 10.34. Roche Diagnostics
  • 10.35. Sanofi-Aventis
  • 10.36. Sensors for Medicine and Science
  • 10.37. Siemens
  • 10.38. Smiths Medical
  • 10.39. SOOIL Development
  • 10.40. Takeda
  • 10.41. TheraFuse
  • 10.42. U.S. Diagnostics
  • 10.43. VeraLight
  • 10.44. Vivus
  • 10.45. Ypsomed Holding

Appendix 1: The History of Insulin

INDEX OF FIGURES

  • Figure 2.1: Worldwide Rates of Diabetes Cases, 2011, 2020 and 2030
  • Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2011
  • Figure 2.3: Prevalence of Diabetes by Age in the U.S, 2010
  • Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2010
  • Figure 2.5: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2011
  • Figure 2.6: How Diabetes Dollars Are Spent in the U.S., 2007
  • Figure 3.1: Maintenance of Normal Blood Sugar Levels
  • Figure 3.2: Obesity (BMI 3 30) Prevalence in U.S. Adults, 2010
  • Figure 3.3: Percentage of Obese Adults in the U.S., 2009-2010
  • Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
  • Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1963-2008
  • Figure 3.6: Annual Death Rate of U.S. Population From Heart Disease, 1950-2008
  • Figure 3.7: Heart Disease Death Rate by Race and Sex in the U.S., 1979-2008
  • Figure 3.8: Annual Death Rate of U.S. Population From Strokes, 1950-2008
  • Figure 3.9: U.S. Male and Female Population Death Rates from Strokes, 2008
  • Figure 3.10: Percentage of U.S. Population that Smokes, 1965-2010
  • Figure 3.11: Percentage of Obese Adults in the U.S., 1960-2008
  • Figure 3.12: Percentage of Obese Children and Adolescents in the U.S., 1971-2008
  • Figure 3.13: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2006-2010
  • Figure 4.1: Top Therapeutic Classes Contributing to Growth in Drug Spending, 2010-2011
  • Figure 4.2: Top Ten Diabetes Medications, by Number of Prescriptions
  • Figure 4.3: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2010
  • Figure 5.1: Comparison of the Effects of the Pioglitazone and Rosiglitazone on Lipids
  • Figure 5.2: Overview of GLP-1 and Blood Glucose
  • Figure 5.3: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2010
  • Figure 5.4: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2010
  • Figure 5.5: Sales Forecast for the Global Diabetes Drug Market, 2008-2016
  • Figure 5.6: Sales Forecast for the U.S. Diabetes Drug Market, 2008-2016
  • Figure 6.1: Global Sales of Lantus (in Euro), 2005-2010
  • Figure 6.2: Insulin Pump Market Share, 2011
  • Figure 9.1: Relationship Between Diabetes Therapy and the Proposed Timeline
  • Figure A1.1: Novo Nordisk's Rising Market Share in the U.S. Insulin Market, 1982-2008

INDEX OF TABLES

  • Table 2.1: Top Ten Countries With the Largest Estimated Number of Diabetics (20 to 79 Years Age Group) 2011 and 2030
  • Table 2.2: U.S. Population of Diabetics (Diagnosed and Undiagnosed) Aged 20 Years or Older, 2010
  • Table 2.3: Cost of Diagnosed Diabetes in the U.S., 2007
  • Table 2.4: Medical Care Costs Attributable to Diabetes in the U.S., 2010
  • Table 2.5: Healthcare Utilization by Diabetic Patients, 2008
  • Table 2.6: Annual Cost of Care of UnitedHealthcare Adult Members with Diabetes, 2009
  • Table 2.7: Per-Event Costs of Diabetes Complications
  • Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.2: American Heart Association and National Heart, Lung and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.3: Additional Metabolic Criteria for Research
  • Table 3.4: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 3.5: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 3.6: Prevalence of Complications Among Patients with Diabetes
  • Table 3.7: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 3.8: Major Causes of End-Stage Renal Disease
  • Table 3.9: Clinical Recommendations for Adults with Diabetes
  • Table 3.10: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.11: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 3.12: Medical Care Costs Attributable to Diabetes in the U.S., 2010
  • Table 3.13: Summary of Cardiovascular Diseases (CVDs)
  • Table 3.14: Death Rate From Cardiovascular Diseases by Country, 2008
  • Table 3.15: Percentage of Adults Smokers by Country, 2008
  • Table 3.16: Selected Potential Patent Expirations of Cardiac Care Drugs, 2012-2013
  • Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2007-2014
  • Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2008-2012
  • Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2011
  • Table 4.3: Leading Therapy Classes for R&D, 2010
  • Table 4.4: Global Pharmaceutical Sales by Region and Country, 2010 and 2015
  • Table 4.5: World Pharmaceutical Sales Share by Region, 2010
  • Table 4.6: Top Ten Global Pharmaceutical Companies by Global Sales, 2011
  • Table 4.7: Leading Ten Therapeutic Classes by U.S. Sales, 2006-2011
  • Table 4.8: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006-2011
  • Table 4.9: Leading Therapy Classes by Global Pharmaceutical Sales, 2015
  • Table 4.10: Top Selling Drugs in the U.S., 2010
  • Table 4.11: Worldwide Anti-Diabetes Drug Market, 2008-2016
  • Table 4.12: Oral Anti-Diabetic Therapy Major World Markets, 2010
  • Table 4.13: The Leading Five Anti-Diabetics by Sales, 2011
  • Table 4.14: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
  • Table 4.15: Summary of Glucose-Lowering Interventions as Monotherapy
  • Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
  • Table 5.2: Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes, 2012
  • Table 5.3: Relative Efficacy of Diabetes Drugs
  • Table 5.4: Average Dose and Cost Comparison of Oral Hypoglycemic Agents
  • Table 5.5: Fixed-Dose Oral Anti-Diabetes Drug Combinations
  • Table 5.6: Delivery Method of Non-Insulin Anti-Diabetes Drugs in the Pipeline, 2011
  • Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development That Target GLP-1
  • Table 5.8: DPP-IV Inhibitor Pipeline
  • Table 5.9: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 6.1: Market Shares of Animal, Human and Modern Insulin, 1995-2010 (% of Total Insulin Market)
  • Table 6.2: Worldwide Insulin Sales, 2008-2016
  • Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2011
  • Table 6.4: Estimated U.S. Retail Insulin Sales, 2011-2015
  • Table 6.5: Worldwide Insulin Sales and Market Share by Company, 2011
  • Table 6.6: U.S. Insulin Sales and Market Share by Company, 2011
  • Table 6.7: Therapeutic Insulins on the Market
  • Table 6.8: Pharmacokinetics of Therapeutic Insulins on the Market
  • Table 6.9: Pharmacokinetics of Short-Acting Insulins
  • Table 6.10: Pharmacokinetics of Rapid-Acting Insulins
  • Table 6.11: Pharmacokinetics of Intermediate-Acting Insuslins
  • Table 6.12: Pharmacokinetics of Long-Acting Insulins
  • Table 6.13: Pharmacokinetics of Insulin Mixtures
  • Table 6.14: Status of Inhaled Insulin Products, 2011
  • Table 6.15: Key Drivers of the Type 2 Diabetes Insulin Market, 2012
  • Table 6.16: A Comparison of Existing Insulin Delivery Devices
  • Table 6.17: Insulin Pens
  • Table 6.18: Estimated Worldwide Demand for Insulin Injector Pens by Volume, 2012-2016
  • Table 6.19: Injection Aids
  • Table 6.20: Jet Injectors
  • Table 6.21: Control Averages by Treatment
  • Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
  • Table 6.23: Leading Insulin Pump Manufacturers
  • Table 6.24: Comparison of Current External Insulin Pumps on the Market
  • Table 6.25: Insulin Infusion Sets
  • Table 6.26: Worldwide Insulin Pump Market, 2009 - 2016
  • Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
  • Table 7.2: Cells of the Pancreas
  • Table 7.3: Lipoprotein Risk Levels and Treatment Goals in Adult Patients with Diabetes
  • Table 7.4: Agents for Lowering Lipid Levels in Patients with Dyslipidemia
  • Table 7.5: Suggested Pharmacological Treatment Agents for Hypertension in Patients with Diabetes
  • Table 8.1: Criteria for the Diagnosis of Diabetes
  • Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
  • Table 8.3: Laboratory Assessment of Diabetic Vascular Disease
  • Table 8.4: Worldwide Glucose Self-Testing Market Sales (Meters and Strips), 2010-2016
  • Table 8.5: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2010-2016
  • Table 8.6: Market Share of U.S. Blood Glucose Self-Testing, 2011
  • Table 8.7: Lancet Characteristics
  • Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2008
  • Table 9.2: Summanry of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 9.3: Selected New Diabetes Drugs in Pipeline, 2011
  • Table 9.4: Comparison of New Molecular Entity Outcomes for FDA and EMEA (Jan 2006 to October 2008)
  • Table 9.5: Recent Milestones for Selected Diabetes Drugs
  • Table 9.6: Overview of Blockbuster Drugs Coming Off-Patent, 2008 to 2012
  • Table A1.1: Select Archived Press Release Excerpts
Show More
Pricing
Get Notified
Email me when related reports are published